NCT02568839View on ClinicalTrials.gov

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2029

Conditions
Early-Stage Breast CarcinomaHER-2 Positive Breast Cancer
Interventions
DRUG

docetaxel + trastuzumab sc + pertuzumab

docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses

DRUG

trastuzumab emtansin

trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses

Trial Locations (7)

17176

Dept. of Oncology, Karolinska University Hospital, Stockholm

Unknown

Dept. of Oncology, Örebro University Hospital, Örebro

Dept. of Oncology, Skåne University Hospital, Lund

Dept. of Oncology, University Hospital of Umeå, Umeå

Dept. of Oncology, Uppsala University Hospital, Uppsala

413 45

Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg

851 86

Dept. of Oncology, Sundsvall Hospital, Sundsvall

All Listed Sponsors
lead

Thomas Hatschek

OTHER